Pfizer has settled an ongoing battle with Teva Pharmaceuticals and several other parties to prevent the sale of Teva’s copycat version of the world’s best-selling drug, Lipitor (atorvastatin).
Under the terms of the agreement Teva, Phoenix Healthcare Distribution, Barclay Pharmaceuticals, AAH Pharmaceuticals, L Rowland & Co and Day Lewis will not the generic before May 2012, when the patent expires.
Go deeper with GlobalData
Pfizer commenced legal proceedings against Teva and three major wholesalers in July.
Upon the decision of a full trial, Pfizer said in a statement that Teva acknowledges that the Lipitor patent is valid and infringed by Teva’s product.
In November, Pfizer will launch a chewable low-dose version of Lipitor in the EU.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
